-
Categories
-
Tags
21 CFR 820.30 21 CFR Part 820 510(k) 510(k) Contents and Format 510(k) format and content 510(k) Requirements 510(k)s 510k 510k In Person Seminar 510k LIVE seminar 510k LIVE Webinar 510K Seminar 510k submission Adverse Event Reporting Adverse Event Reporting Systems Advertising and Promotion AERS AIMDD ANDA Animal Drugs Asian Country Big Data Biocompatibility Biologics Biosimilars BLA CAPA CDRH CE Mark China Complaint Complaint Handling David Lim Design Control Dr. David Lim Drugs EMA EN ISO 13485:2012 EN ISO 14971:2012 EU EU Marketing Authorization Application (MAA) FDA FDA 510(k) FDA 510(k) Seminar: Best Practices for 510(k) Preparation FDA Guidance FDA Inspection FDA-Regulated Industry FMEA Fundamentals of Regulatory Affairs Generics Global Compliance Seminar Hatch-Waxman Act Healthcare Industry Hong Kong Human Drug IDE IND ISO 13485 ISO 14155 IVDD IVDs Japan Korea Laws and Regulations LIVE 510(k) Webinar LIVE Online Seminar LIVE Webinar MAA to EMA in EU Mandatory Adverse Event Reporting Marketing Approvals for Generic Medicines MDD MDR Medical Device Medical Device Reporting Medical Devices Medicine NDA Opioid Abuse Opioid Addiction Opioids Pain Management Paragraph IV Certification Patent Patent Exclusivity PMA PMA Drafting Seminar PMA Seminar PMAs Postmarket Surveillance Postmarket Vigilance Pre-submission Premarket Approval Premarket Notification Q-Submission QSR Quality Risk Management Quality System Regulation Recorded Recorded 510k Seminar Recorded PMA Seminar reference listed drug Regulatory Affairs Regulatory Doctor Regulatory Plan Regulatory Plan/Strategy Regulatory Requirements Regulatory Strategy Risk Analysis Risk Management RLD Safety Signals Social Media Marketing Social Media Practice Social Media Practices SOPs Submission and Clearance | Global Compliance Seminar substantial equivalence UDI Unique Device Identification Unique Device Identifier US FDA US FDA 510(k) US RAC Exam Writing an Effective SOP
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299
LIVE Online Seminar
Establishing FDA-Compliant Social Media Practices to Avoid FDA Actions
- Date: December 9, 2016
- NOTE: This seminar recurrs bi-monthly on second Fridays.
- Time: 09:00 AM PST | 12:00 PM EST
- Duration: 60 Minutes.
About the Seminar
This seminar is intended to help you adequately implement good social media practices to avoid FDA enforcement actions for potential misbranding of your prescription drugs (humans and animals), biologics, and medical devices including other healthcare products (dietary supplements, cosmetics and OTCs).
On June 27, 2014, FDA issued an untitled letter to a pharmaceutical company concerning the firm’s sponsored link on the internet search engine. FDA states:
The sponsored link provides evidence that the drug is intended for a new use for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders the drug misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) or otherwise makes its distribution violative.
The U.S. Food and Drug Administration (FDA) reviewed the firm’s sponsored link on the Google as part of the FDA’s routine monitoring and surveillance program by the Office of Prescription Drug Promotion (OPDP). It is imperative that firms ensure their compliance to the applicable laws and regulations when they provide drug or device information to the public through social media.
In this presentation, the speaker will discuss what to consider and how to establish your good social media practices while ensuring your compliance to the laws and regulation to avoid potential FDA enforcement actions.
This 60 min seminar presentation will provide you a great opportunity to understand FDA’s perspective on social media practices covered in FDA’s recent guidances. You will learn about the various considerations that pharmaceutical and medical device firms need to consider when establishing procedures for social media practices.
About the Areas to Be Discussed
- Applicable Laws and Regulations
- Definitions
- FDA’s Current Thinking and Perspectives
- FDA’s Three (3) Social Media Guidances Issued in December, 2011 and June, 2014
- Best Social Media Practices
- FDA Enforcements: Recent Cases
- Advertising and Promotion on Social Media – Twitter, Facebook, YouTube, WordPress and Blogger
- PASS-IT Recommendations: Dos and Don’ts
About the Intended Attendee(s)
- R&D Scientists, Managers, Directors, and VPs
- Regulatory Affairs and Compliance Professionals
- Clinical Affairs Professionals
- Quality Professionals
- Consultants
- Legal and Compliance Officers
- Marketing Professionals
- Senior Management
- Anyone Interested in the Subject
About the Seminar Speaker

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules and guidance applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed premarket notification 510(k) and premarket approval (PMA) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase below using a credit card or PayPal below.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 5 attendees): $599
LIVE (≥ 6 attendees): $999
LIVE & Recorded: $299